GAMMA Investing LLC Sells 1,024 Shares of Avantor, Inc. (NYSE:AVTR)

GAMMA Investing LLC decreased its position in Avantor, Inc. (NYSE:AVTRFree Report) by 37.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,691 shares of the company’s stock after selling 1,024 shares during the quarter. GAMMA Investing LLC’s holdings in Avantor were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp raised its holdings in Avantor by 58.0% in the third quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after purchasing an additional 8,206,695 shares in the last quarter. 1832 Asset Management L.P. increased its holdings in shares of Avantor by 1,634.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after purchasing an additional 8,038,451 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after purchasing an additional 5,354,678 shares in the last quarter. FMR LLC increased its holdings in Avantor by 557.2% in the 3rd quarter. FMR LLC now owns 4,675,283 shares of the company’s stock worth $120,950,000 after buying an additional 3,963,912 shares in the last quarter. Finally, Sound Shore Management Inc. CT bought a new stake in shares of Avantor in the second quarter worth approximately $76,412,000. 95.08% of the stock is owned by institutional investors.

Avantor Stock Down 1.4 %

Avantor stock opened at $21.71 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm has a 50 day moving average price of $21.49 and a 200 day moving average price of $23.36. Avantor, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $28.00. The company has a market capitalization of $14.78 billion, a PE ratio of 47.20, a price-to-earnings-growth ratio of 2.75 and a beta of 1.28.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AVTR shares. Barclays reduced their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, October 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Avantor in a report on Thursday, September 26th. UBS Group cut their price target on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Finally, Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.69.

Read Our Latest Stock Report on Avantor

About Avantor

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

See Also

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTRFree Report).

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.